Patrick Dallemagne

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 34

Top Venues

Molecules (Basel, Switzerland)

Future medicinal chemistry

Nature communications

Cell death & disease

Université de Caen Normandie

Université de Caen Normandie (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Université de Caen Normandie

France

Dean :: CERMN

Université de Caen Normandie

France

Professor CEx2 :: Faculty of Pharmacy

Université de Caen Normandie

France

Dean :: Faculty of Pharmacy

Université de Caen Normandie

France

Deputy President

Education History

Université de Caen Normandie

France

PHD :: Faculty of Pharmacy

Université Paris-Sud

France

MSC :: Faculty of Pharmacy

Publications

Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Alaa Al Assi, Solène Posty, Frédéric Lamarche, Amel Chebel, Jérôme Guitton, Cécile Cottet-Rousselle, Renaud Prudent, Laurence Lafanechère, Stéphane Giraud, Patrick Dallemagne, Peggy Suzanne, Aurélie Verney, Laurent Genestier, Marie Castets, Eric Fontaine, Marc Billaud, Martine Cordier-Bussat
A novel inhibitor of the mitochondrial respiratory complex I with uncoupling properties exerts potent antitumor activity. Cell death & disease 15 (5) (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Alaa Al Assi, Solène Posty, Frédéric Lamarche, Amel Chebel, Jérôme Guitton, Cécile Cottet-Rousselle, Renaud Prudent, Laurence Lafanechère, Stéphane Giraud, Patrick Dallemagne, Peggy Suzanne, Aurélie Verney, Laurent Genestier, Marie Castets, Eric Fontaine, Marc Billaud, Martine Cordier-Bussat
A novel inhibitor of the mitochondrial respiratory complex I with uncoupling properties exerts potent antitumor activity. Cell death & disease 15 (5) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Alaa Al Assi, Solène Posty, Frédéric Lamarche, Amel Chebel, Jérôme Guitton, Cécile Cottet-Rousselle, Renaud Prudent, Laurence Lafanechère, Stéphane Giraud, Patrick Dallemagne, Peggy Suzanne, Aurélie Verney, Laurent Genestier, Marie Castets, Eric Fontaine, Marc Billaud, Martine Cordier-Bussat
A novel inhibitor of the mitochondrial respiratory complex I with uncoupling properties exerts potent antitumor activity. Cell death & disease 15 (5) (2024)
Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Thomas Guiselin, Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne
Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer's Disease. Pharmaceutics 15 (10) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Valentin Travers-Lesage, Serge M Mignani, Patrick Dallemagne, Christophe Rochais
Advances in prodrug design for Alzheimer's disease: the state of the art. Expert opinion on drug discovery 17 (4) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Cédric Lecoutey, Rémi Legay, Audrey Davis, Jana Sopková-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer's Disease Treatment through Rigidification Strategy. Molecules (Basel, Switzerland) 26 (9) (2021)
Patrick Dallemagne, Christophe Rochais
5-HT4R modulators: a patent landscape. Pharmaceutical patent analyst 10 (4) (2021)
Line Séguy, Léna Guyon, Manon Maurel, Pascal Verdié, Audrey Davis, Sophie Corvaisier, Vincent Lisowski, Patrick Dallemagne, Anne-Claire Groo, Aurélie Malzert-Freon
Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment. Pharmaceutics 13 (10) (2021)
Pauline Zipfel, Christophe Rochais, Kévin Baranger, Santiago Rivera, Patrick Dallemagne
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges. Journal of medicinal chemistry 63 (19) (2020)
Christophe Rochais, Cédric Lecoutey, Katia Hamidouche, Patrizia Giannoni, Florence Gaven, Eleazere Cem, Serge Mignani, Kevin Baranger, Thomas Freret, Joël Bockaert, Santiago Rivera, Michel Boulouard, Patrick Dallemagne, Sylvie Claeysen
Donecopride, a Swiss army knife with potential against Alzheimer's disease. British journal of pharmacology 177 (9) (2020)
Lauralie Peronne, Eric Denarier, Ankit Rai, Renaud Prudent, Audrey Vernet, Peggy Suzanne, Sacnicté Ramirez-Rios, Sophie Michallet, Mélanie Guidetti, Julien Vollaire, Daniel Lucena-Agell, Anne-Sophie Ribba, Véronique Josserand, Jean-Luc Coll, Patrick Dallemagne, José Fernando Díaz, María Ángela Oliva, Karin Sadoul, Anna Akhmanova, Annie Andrieux, Laurence Lafanechère
Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells. Cancers 12 (8) (2020)
Caroline Lanthier, Patrick Dallemagne, Cédric Lecoutey, Sylvie Claeysen, Christophe Rochais
Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present). Expert opinion on therapeutic patents 30 (7) (2020)
Jean-Pierre Jourdan, Ronan Bureau, Christophe Rochais, Patrick Dallemagne
Drug repositioning: a brief overview. The Journal of pharmacy and pharmacology 72 (9) (2020)
Benjamin Guieu, Cedric Lecoutey, Rémi Legay, Audrey Davis, Jana Sopkova de Oliveira Santos, Cosimo Damiano Altomare, Marco Catto, Christophe Rochais, Patrick Dallemagne
First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease. Molecules (Basel, Switzerland) 26 (1) (2020)
François-Xavier Toublet, Cédric Lecoutey, Julien Lalut, Bérénice Hatat, Audrey Davis, Marc Since, Sophie Corvaisier, Thomas Freret, Jana Sopkova de Oliveira Santos, Sylvie Claeysen, Michel Boulouard, Patrick Dallemagne, Christophe Rochais
Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease. Molecules (Basel, Switzerland) 24 (15) (2019)
Jean-Pierre Jourdan, Marc Since, Laïla El Kihel, Cédric Lecoutey, Sophie Corvaisier, Rémi Legay, Jana Sopkova-de Oliveira Santos, Thierry Cresteil, Aurélie Malzert-Fréon, Christophe Rochais, Patrick Dallemagne
Benzylphenylpyrrolizinones with Anti-amyloid and Radical Scavenging Effects, Potentially Useful in Alzheimer's Disease Treatment. ChemMedChem 12 (12) (2017)
Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, Marc Since, Valentine Bouet, Céline Ballandonne, Sophie Corvaisier, Aurélie Malzert Fréon, Serge Mignani, Thierry Cresteil, Michel Boulouard, Sylvie Claeysen, Christophe Rochais, Patrick Dallemagne
Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proceedings of the National Academy of Sciences of the United States of America 111 (36) (2014)

Patrick Dallemagne.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Patrick Dallemagne